お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
市場調査レポート
商品コード
927865

心停止治療市場:成長、動向、予測(2020~2025)

Cardiac Arrest Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 120 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.75円
心停止治療市場:成長、動向、予測(2020~2025)
出版日: 2020年08月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 120 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の心停止治療市場は、2020年から2025年にかけて4.8%のCAGRで拡大すると予測されています。さまざまな冠状動脈性心臓病の有病率の増加、心停止によって死亡につながる心筋症、老年人口の増加等の要因により、即時性のある治療の需要が高まっています。

当レポートでは、心停止治療の世界市場を調査し、市場の概要、タイプ、地域別の市場動向、市場規模の推移と予測、市場促進・阻害要因ならびに市場機会の分析、競合情勢、主要企業のプロファイルなど包括的な情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場のダイナミクス

  • 市場概要
  • 成長要因
    • 脳卒中や冠状動脈性心不全などの心臓疾患の世界の有病率の上昇
    • 技術的に進歩した製品の利用可能性と償還方針
  • 抑制要因
    • 経皮的冠動脈インターベンションなどの低侵襲的処置の採用
    • 高度なヘルスケアインフラストラクチャ、熟練した専門家、高額な治療法の欠如
  • ファイブフォース分析

第5章 市場セグメンテーション

  • 治療別
    • 薬物
    • 医療機器
  • 流通チャネル別
    • 病院
    • 薬局
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Koninklijke Philips NV
    • Boston Scientific Corporation
    • GE Healthcare
    • Abbott Laboratories
    • Novartis International AG
    • Johnson & Johnson
    • Pfizer Inc.
    • Amgen Inc
    • METsis Medikal
    • Medtronic plc

第7章 市場機会および将来動向

目次
Product Code: 68216

The cardiac arrest treatment market studied was anticipated to witness a CAGR of nearly 4.8%, during the forecast period. The major factors driving the growth of the market are the increasing prevalence of various coronary heart diseases, cardiomyopathy, which is leading to cardiac arrest deaths, favorable reimbursement initiatives, and a rise in the geriatric population. For instance, according to Global Health and Wellness Report published in 2018, nearly 40% of the adult population in the United States were diagnosed with a cardiovascular condition, which directly resulted in higher demand for highly efficient, immediate treatment, and better technological advanced cardiovascular devices, which is expected to fuel the growth of the market throughout the forecast period.

Key Market Trends

The Drug Segment is Expected to Hold the Largest Market Share in the Cardiac Arrest Treatment Market

  • The drug segment is expected to witness the largest market share in the cardiac arrest treatment market during the forecast period. This dominance is due to the increased use of various drugs such as anticholinergics, beta-blockers, vasopressors, and fibrinolytic drugs owing to the rise in prescriptions by the cardiologists.
  • Furthermore, anti-arrhythmic drugs are widely used by most patients for the treatment of potential arrhythmia and during emergencies to save the person from heart failure or cardiac arrest. On the other hand, medical devices such as defibrillators and cardiac resynchronization therapy (CRT) are gaining attraction in recent years. They are anticipated to witness significant growth in the forecast period due to rising awareness among the patients. Furthermore, the growth can be attributed to the rise in usage by the people who are expected to face cardiac arrest problems in the near future.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall cardiac arrest treatment market throughout the forecast period. The major factors attributing to the growth are a rise in the global prevalence of multiple cardiovascular indications like CAD, strokes, and atrial fibrillation, along with the increase of chronic diseases, such as diabetes and obesity, necessitating efficient cardiac arrest treatment. For instance, according to The American Heart Association, in 2018, nearly 92.1 million individuals in the country suffered from cardiovascular diseases. CAD was the primary cause of death that resulted in higher demand for better treatment technologies, driving the market in the United States and contributing to the outstanding share of revenue; thus, propelling the global cardiac arrest treatment market throughout the forecast period.

Competitive Landscape

The cardiac arrest market is moderately competitive and consists of several major players. Few of the key players are developing the novel product and technologies to compete with the existing products while others are acquiring and partnering with the other companies trending in the market. For instance, in January 2017, Abbott acquired St. Jude Medical and expanded its medical device segment globally by adding breakthrough inventions of SJM to its existing product portfolio of cardiovascular devices, such as the Quadra Allure MP CRT-P, used as cardiac resynchronization therapy in managing cardiac failure, which is further expected to foster the global cardiac arrest market growth throughout the forecast period. Some of the companies which are currently dominating the market are Koninklijke Philips NV, Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, and Novartis AG.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Global Prevalence of Cardiac Disorders, such as Strokes and Coronary Heart Failures
    • 4.2.2 Availability of Technologically Advanced Products and Reimbursement Policies
  • 4.3 Market Restraints
    • 4.3.1 Adoption of Minimally Invasive Procedures like Percutaneous Coronary Interventions
    • 4.3.2 Lack of Advanced Healthcare Infrastructure, Skilled Professionals, and Highly Expensive Treatments
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment
    • 5.1.1 Drugs
      • 5.1.1.1 Vasopressors
      • 5.1.1.2 Anti-arrhythmic Drugs
      • 5.1.1.3 Anticholinergic Drugs
      • 5.1.1.4 Antihypertensives
      • 5.1.1.5 Other Drugs
    • 5.1.2 Medical Devices
      • 5.1.2.1 Cardiac Resynchronization Therapy (CRT)
      • 5.1.2.2 Defibrillators
      • 5.1.2.3 Other Medical Devices
  • 5.2 By Distribution Channel
    • 5.2.1 Hospitals
    • 5.2.2 Pharmacies
    • 5.2.3 Other Distribution Channels
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United states
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Koninklijke Philips NV
    • 6.1.2 Boston Scientific Corporation
    • 6.1.3 GE Healthcare
    • 6.1.4 Abbott Laboratories
    • 6.1.5 Novartis International AG
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Pfizer Inc.
    • 6.1.8 Amgen Inc.
    • 6.1.9 METsis Medikal
    • 6.1.10 Medtronic PLC

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.